胰激肽原酶联合金水宝治疗糖尿病肾脏病的临床疗效观察

Clinical Efficacy of Pancreatic Kininogenase Combined with Jinshuibao in the Treatment of Diabetic Kidney Disease

目的:探讨胰激肽原酶联合金水宝治疗糖尿病肾病的临床疗效。方法:选择某院2011年8月~2016年8月收治的322例糖尿病肾脏病患者作为研究对象,随机分为对照组和研究组,每组161例。对照组患者采用胰激肽原酶治疗,研究组在对照组的基础上联合金水宝治疗,治疗3个月后,比较两组患者的治疗效果。结果:研究组及对照组患者治疗总有效率分别为93.79%、79.50%,两组比较差异性显著(P<0.05);观察组治疗后FBG、HbA1c优于对照组(P<0.05);观察组治疗后两组患者24h尿蛋白、SCr、血清ALB及BUN优于对照组(P<0.05)。结论:胰激肽原酶与金水宝联合应用可有效缓解糖尿病肾脏病患者的病情,减少尿蛋白排泄量,临床疗效显著,值得推广应用。

Objective:To investigate the clinical efficacy of pancreatic kininogenase combined with Jinshibao in the treatment of diabetic nephropathy.Methods:322 diabetic patients with diabetic nephropathy treated in a hospital from August 2011 to August 2016were selected and randomly divided into control group and treatment group,with 161 cases in each group.The patients in the control group were treated with pancreatic kininogenase,and the study group was treated with Jinshuibao on the basis of the control group.After 3 months of treatment,the therapeutic effects of the two groups were compared.Results:The total effective rate of the patients in the study group and the control group was 93.79%and 79.50%,respectively.The difference between the two groups was significant(P<0.05).The study group was superior to the control group in FBG HbA1c after treatment(P<0.05).The levels of urinary protein,SCr,serum ALB and BUN in the study group were better than those in the control group(P<0.05).Conclusion:The combination of pancreatic kallikrein and Jinshuibao can effectively alleviate the condition of diabetic patients with kidney disease and reduce the excretion of urine protein,with remarkable clinical effect,which is worthy of promotion and application.